Clinical Trials Logo

Clinical Trial Summary

An observational study in patients between 12 and 70 years old with an acute asthma exacerbation, to determine the relation between phenotypical characteristics and the treatment response.


Clinical Trial Description

Rationale: Asthma is a heterogeneous inflammatory respiratory disease affecting 8 - 9% of the European population. Acute asthma exacerbation (AAE) is characterized as an acute worsening of symptoms and is treated inconsistently with steroids with or without antibiotics. In order to adjust and personalise exacerbation treatment, phenotyping and classifying of asthma exacerbations would be required. Therefore, we want to classify patients with AAEs phenotypically in relation to the treatment response. Objective: The primary objective of the study is to determine the relationship between exacerbation treatment response at day 7 and the phenotypical characteristics of asthma exacerbations. Secondary objectives are 1) developing a prediction model based on biomarkers and/or clinical data to predict the treatment response of AAEs 2) comparing the environmental, inflammatory, microbiological and lipid parameters of patients diagnosed with asthma between exacerbation phase and recovery (baseline). Study design: A prospective cohort multicentre study. Study population: Patients aged 12 - 70 years, diagnosed with mild to severe asthma according to the Global Initiative for Asthma (GINA) guidelines. Patients will be included at the onset of a severe asthma exacerbation. Main study parameters/endpoints: Primary endpoint is the relation of phenotypical characteristics with treatment response at day 7, defined by 1) the physician - and patient rated global evaluation of treatment effectiveness (GETE) score 2) difference in Asthma Control Questionnaire 5 (ACQ-5) (> 0.5) 3) difference in handheld spirometry values like forced expiratory volume (FEV1 ≥ 10%). Treatment response will be classified as excellent, good, moderate or poor. Secondary endpoints are 1) a prediction model for the treatment response of AAE 2) aetiology of the AAE 3) blood and local respiratory parameters; microbiota composition; lipid metabolomics and volatile compounds composition at baseline and AAE. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05304039
Study type Observational
Source Franciscus Gasthuis
Contact Anne-Lotte Redel, MD
Phone +31613320538
Email a.redel2@franciscus.nl
Status Recruiting
Phase
Start date September 28, 2022
Completion date May 2025

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04410120 - Impact of Asthma Exacerbations
Not yet recruiting NCT03277170 - Pragmatic RCT of High-dose Oral Montelukast for Moderate and Severe Pediatric Acute Asthma Exacerbations Phase 2
Completed NCT03967873 - Child Asthma : What Parents Attitude During an Asthma Attack at Home Before Consulting the Pediatric Emergencies
Completed NCT05908864 - Nebulized Versus Intravenous Magnesium Sulfate in Treatment of Asthma Exacerbation
Completed NCT05318885 - The Effect of Nebulization Positions in Asthmatic Children N/A
Recruiting NCT06137040 - Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation Early Phase 1
Recruiting NCT05446090 - Asthma: Phenotyping Exacerbations 3
Enrolling by invitation NCT06201728 - The Effect of Asthma Flare-up Clinic After Exacerbation N/A
Terminated NCT05013073 - ASTHMAXcel Emergency Department Study N/A
Recruiting NCT05603494 - The Use of Home Spirometry in the Monitoring of Patients With Acute Exacerbation of Asthma N/A
Completed NCT03099915 - Asthma Attack in the Emergency Department : Reasons Of This Attendance
Recruiting NCT04501926 - Genomics and Metagenomics of Asthma Severity
Recruiting NCT05417906 - Using the Blood Eosinophil Count to Guide Systemic Corticosteroid Treatment in Asthma Exacerbations Phase 2
Recruiting NCT04617171 - Benralizumab Initiated During Severe Asthma Attack Phase 2
Recruiting NCT05748600 - A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Phase 3
Completed NCT03705325 - Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer N/A
Completed NCT04941001 - Optimisation of ASthma In Those With Uncontrolled Symptoms (OASIS) N/A
Completed NCT03642418 - User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
Not yet recruiting NCT06377345 - Remote Patient Monitoring Solution for Chronic Respiratory Disease Management N/A